ASCO®

AMERICAN SOCIETY OF CLINICAL ONCOLOGY

KNOWLEDGE CONQUERS CANCER

# 2025 Coding Updates and Changes for Oncology:

# CPT®, HCPCS, and ICD-10

---

## April 2025

# Contents

# 2025 Current Procedural Terminology (CPT)
# New, Revised and Deleted CPT® Codes for Oncology

This resource is a summary of the CPT coding changes effective **January 1st, 2025**. For full details and guidelines, please refer to the 2025 American Medical Association CPT® Professional Edition.

## New CPT® Codes

### Telemedicine Services

A new section has been added for telemedicine services within the Evaluation and Management section. These services are synchronous, real-time, interactive encounters utilizing either audio-video or audio-only technology and are utilized in the same manner as in-person E/M services. Level selection still follows E/M guidelines based on medical decision-making or total time on the date of the encounter.

#### Synchronous Audio-Video

New Patient

| Code | Medical-Decision Making | Time |
|---|---|---|
| 98000 | Straightforward | 15 minutes |
| 98001 | Low | 30 minutes |
| 98002 | Moderate | 45 minutes |
| 98003 | High | 60 minutes |

Established Patient

| Code | Medical-Decision Making | Time |
|---|---|---|
| 98004 | Straightforward | 10 minutes |
| 98005 | Low | 20 minutes |
| 98006 | Moderate | 30 minutes |
| 98007 | High | 40 minutes |

## Synchronous Audio-Only

All audio-only evaluation and management visits require at least 10 minutes of medical discussion with the patient.

### New Patient

| Code | Medical-Decision Making | Time |
|---|---|---|
| 98008 | Straightforward | 15 minutes |
| 98009 | Low | 30 minutes |
| 98010 | Moderate | 45 minutes |
| 98011 | High | 60 minutes |

### Established Patient

| Code | Medical-Decision Making | Time |
|---|---|---|
| 98012 | Straightforward | 10 minutes |
| 98013 | Low | 20 minutes |
| 98014 | Moderate | 30 minutes |
| 98015 | High | 40 minutes |

## Virtual Check-In

98016 Brief (synchronous) communication technology-based services by a physician or qualified healthcare professional who can report E/M services, provided to an established patient, not originating from a related E/M services within the previous 7 days or leading to an E/M or procedure within the next 24 hours or soonest available appointment, and requires 5-10 minutes of medical discussion.

## Pathology and Laboratory Services

### Proprietary Laboratory Analysis (PLA) Codes – Appendix O

0420U Oncology (urothelial), mrna expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma

0421U Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 rna markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, EGLN2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk

0422U Oncology (pan-solid tumor), analysis of dna biomarker response to anti-cancer therapy using cell-free circulating dna, biomarker comparison to a previous baseline pre-treatment cell-free circulating dna analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate

0424U Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer

0428U Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor dna (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden

0433U Oncology (prostate), 5 dna regulatory markers by quantitative pcr, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer

0435U Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations

0436U Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy

0444U Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)

0448U Oncology (lung and colon cancer), DNA, qualitative, next generation sequencing detection of single-nucleotide variants and deletions in EGFR and KRAS genes, formalin-fixed paraffin embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options

0450U Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides

0451U Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance

0452U Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer

0453U Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)

0458U Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score

0460U Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes

0461U Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes

0463U Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker

0464U Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result

0465U Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative

0467U Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden

0470U Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma

0471U Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin-fixed paraffin-embedded (FFPE), predictive, identification of detected mutations

0473U Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden

0474U Hereditary pan-cancer (e.g., hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene

0475U Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer

## Medicine

### Cellular and Gene Therapies

The guidelines included in this section define and summarize what CAR-T therapy is intended to do.

Previous category III codes for Chimeric Antigen Receptor Therapy services will be replaced in 2025 with new Category I codes. Each code may be reported only once per day. Care

provided on the date of the encounter that is not related to the CAR-T service may be reported separately using an appropriate modifier. Management of uncomplicated adverse events is included in the infusion administration service, as are fluids used to administer the cells, any incidental hydration, and any concurrent supportive medication if related to the CAR-T administration. The modification of the cells in an outside laboratory is not included in the service, as the work is done separately from that of which is described in the code descriptors.

38225 Chimeric antigen receptor T-cell therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day

38226 preparation of blood-derived T lymphocytes for transportation (e.g., cryopreservation, storage)

38227 receipt and preparation of CAR-T cells for administration

38228 CAR-T cell administration, autologous

### Category II and III codes

*Category II codes are used to record performance measurement. Category III codes are temporary codes assigned for emerging technology, services, procedures, and paradigms. Category II and III codes facilitate data collections and are not assigned relative value; therefore, these codes are not reimbursable.*

0901T Placement of bone marrow sampling port, including imaging guidance when performed

## Revised CPT® Codes

Inconsistent use of the phrase “qualified non-physician health care professional” throughout the CPT code set has been modified in some instances to indicate a non-physician role may provide the service.

### Pathology and Laboratory Services

#### Proprietary Laboratory Analysis (PLA) Codes

0047U Revision to proprietary name: ~~Oncotype DX Genomic Prostate Score, Genomic Health, Inc, Genomic Health, Inc~~ Genomic Prostate Score® (GPS) Test, MDxHealth, Inc, MDxHealth, Inc

0356U Oncology (oropharyngeal **or anal**), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence

### Vaccines

90661 Influenza virus vaccine, trivalent (ccIV3), derived from cell cultures, subunit, ~~preservative and~~ antibiotic free, 0.5 mL dosage, for intramuscular use

## Deleted CPT Codes

### Evaluation and Management Services

*The following codes have been replaced with appropriate telemedicine codes*.

99441-99443 Telephone evaluation and management services by a physician or other qualified health care professional to an established patient, parent, or guardian not originating from a related E/M service within the previous 7 days nor leading to an E/M service within the next 24 hours or soonest available appointment

### Propriety Laboratory Analysis (PLA) Codes

0204U Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected
Afirma Xpression Atlas, Veracyte, Inc, Veracyte, Inc

### Vaccines

90630 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use

90654 Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use

### Category II and III codes

0537T-0540T have been deleted. Chimeric antigen receptor T-cell therapy should be reported with new Category I codes.

## Guideline Changes

### Medicine

## Cellular and Gene Therapies

The guidelines included in this section define and summarize what CAR-T therapy is intended to do.

Each code may be reported only once per day. Care provided on the date of the encounter that is not related to the CAR-T service may be reported separately using an appropriate modifier. Management of uncomplicated adverse events is included in the infusion administration service, as are fluids used to administer the cells, any incidental hydration, and any concurrent supportive medication if related to the CAR-T administration. The modification of the cells in an outside laboratory is not included in the service, as the work is done separately from that of which is described in the code descriptors.

# Healthcare Common Procedure Coding System Update

The Centers for Medicare and Medicaid Services (CMS) publishes updates to the Healthcare Procedure Coding System (HCPCS) on a quarterly basis. Public use files may be downloaded from the "HCPCS Quarterly Update" page. Be sure to update any systems accordingly.

## Drugs

### NEW Codes

C9163 Injection, talquetamab-tgvs, 0.25mg (January 1st)

C9165 Injection, elranatamab-bcmm, 1mg (January 1st)

C9169 Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

C9170 Injection, tarlatamab-dlle, 1 mg

C9171 Injection, peguliacianine, 1 mg

J1323 Injection, elranatamab-bcmm, 1 mg

J1434 Injection, fosaprepritant (focinvez), 1 mg

J2277 Injection, motixafortide, 0.25 mg

J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to J2469, 25 micrograms

J3055 Injection, talquetamab-tgvs, 0.25 mg

J3263 Injection, toripalimab-tpzi, 1 mg

J8522 Capecitabine, oral, 50 mg

J8541 Dexamethasone (hemady), oral, 0.25 mg

J8611 Methotrexate (Jylamvo), oral, 2.5 mg

J8612 Methotrexate (Xatmep), oral, 2.5 mg

J9052 Injection, carmustine (accord), not therapeutically equivalent to J9050, 100mg

J9072 Injection, cyclophosphamide, (dr. reddy's), 5 mg

J9073 Injection, cyclophosphamide (ingenus), 5 mg

J9074 Injection, cyclophosphamide (sandoz), 5 mg

J9075 Injection, cyclophosphamide, not otherwise specified, 5 mg

J9172 Injection, docetaxel (ingenus) not therapeutically equivalent to J9171, 1 mg (See Revised Codes, Eff 10-1-2024)

J9248 Injection, melphalan (heptazo), 1 mg

J9249 Injection, melphalan (apotex), 1 mg

J9255 Injection, methotrexate (accord) not therapeutically equivalent to J9250 or J9260, 50 mg

J9258 Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to J9264, 1 mg

J9286 Injection, glofitamab-gxbm, 2.5 mg

J9321 Injection, epcoritamab-bysp, 0.16 mg

J9324 Injection, pemetrexed (pemrydi rtu), 10 mg

J9329 Injection, tislezumab-jsgr, 1 mg

J9361 Injection, efbemalenograstim alfa-vuxw, 0.5 mg

Q5136 Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg

REVISED Codes

J9260 **Injection,** methotrexate sodium, 50 mg

J9172 Injection, docetaxel **(docivyx)** ~~(Ingenus), not therapeutically equivalent to J9171,~~ 1 mg

Q2055 Idecabtagene vicleucel, up to **510** ~~460~~ million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

DISCONTINUED Codes

C9155 Injection, epcoritamab-bysp, 0.16 mg

C9163 Injection, talquetamab-tgvs, 0.25 mg

C9165 Injection, elranatamab-bcmm, 1 mg

J2780 Injection, ranitidine hydrochloride, 25 mg

J8520 Capecitabine, oral, 150 mg

J8521 Capecitabine, oral 500 mg

J9070 Cyclophosphamide, 100 mg

J9160 Injection, denileukin difitox, 300 micrograms

J9250 Methotrexate sodium, 5 mg

J9258 Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to J9264, 1 mg

J9371 Injection, vincristine sulfate liposome, 1 mg

## Medical and Surgical Supplies

### NEW Codes

A9608 Flotufolastat f18, diagnostic, 1 millicurie

A9609 Fludeoxyglucose f18, up to 15 millicuries

### DISCONTINUED Codes

C9156 Flotufolastat f18, diagnostic, 1 millicurie

C9788 Opto-acoustic imaging, breast (including axilla when performed), unilateral, with image documentation, analysis and report, obtained with ultrasound examination

## Modifiers

### REVISED codes

TB Drug or biological acquired with 340B pricing program discount, reported for informational purposes

### DISCONTINUED Codes

JG Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes

*See ASCO's Drug Waste Modifier Resource for more information on reporting the correct 340B modifier.*

## Procedures

### NEW Codes

C9794 Therapeutic radiology simulation-aided field setting; complex, including acquisition of PET and CT imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling)

C9795 Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and read-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions

## ICD-10-CM Updates

The Centers for Medicare and Medicaid Services published ICD-10 CM updates effective **October 1st, 2024** through **September 30th, 2025.** Several new codes and changes were made in Chapter 2 (Neoplasms) to indicate remission status of lymphoma and lymphoid disease as well as Chapter 21 (Factors influencing health status and contact with health services).

A full list of changes can be found in the "Addendum" files on the ICD-10 CM updates page. Questions about ICD-10 CM codes may be sent to ASCO at practice@asco.org.

### Guidelines

There are minor editorials changes (i.e., clarifying words, revised ICD-10-CM codes) in the guidelines, specifically regarding neoplasm coding. However, the revisions do not change the intent or interpretation of the guidelines.

### ICD-10 CM Code Set

#### Additions

| Reference Code Family | New/Added Codes |
|---|---|
| C81 Hodgkin lymphoma | C81.0A Nodular lymphocyte predominant Hodgkin lymphoma, in remission |
| | C81.1A Nodular sclerosis Hodgkin lymphoma, in remission |
| | C81.2A Mixed cellularity Hodgkin lymphoma, in remission |

| | |
|---|---|
| | C81.3A Lymphocyte depleted Hodgkin lymphoma, in remission |
| | C81.4A Lymphocyte-rich Hodgkin lymphoma, in remission |
| | C81.7A Other Hodgkin lymphoma, in remission |
| | C81.9A Hodgkin lymphoma, unspecified, in remission |
| C82 Follicular lymphoma | C82.0A Follicular lymphoma grade I, in remission |
| | C82.1A Follicular lymphoma grade II, in remission |
| | C82.2A Follicular lymphoma grade III, unspecified, in remission |
| | C82.3A Follicular lymphoma grade IIIa, in remission |
| | C82.4A Follicular lymphoma grade IIIb, in remission |
| | C82.5A Diffuse follicle center lymphoma, in remission |
| | C82.6A Cutaneous follicle center lymphoma, in remission |
| | C82.8A Other types of follicular lymphoma, in remission |
| | C82.9A Follicular lymphoma, unspecified, in remission |
| C83 Non-follicular lymphoma | C83.0A Small cell B-cell lymphoma, in remission |
| | C83.1A Mantle cell lymphoma, in remission |
| | C83.390 Primary central nervous system lymphoma<br>Excludes 1: Primary central nervous system lymphoma, Burkitt (C83.79)<br>Primary central nervous system lymphoma, lymphoblastic (C83.59)<br>Primary central nervous system lymphoma, other (C83.89)<br>Primary central nervous system lymphoma, peripheral T-cell (C84.49) |
| | C83.398 Diffuse large B-cell lymphoma of other extranodal and solid organ sites |
| | C83.3A Diffuse large B-cell lymphoma, in remission |
| | C83.5A Lymphoblastic (diffuse) lymphoma, in remission |
| | C83.7A Burkitt lymphoma, in remission |
| | C83.8 Other non-follicular lymphoma, in remission |
| | C83.9A Non-follicular (diffuse) lymphoma, unspecified, in remission |

| | |
|---|---|
| C84 Mature T/NK-cell lymphomas | C84.0A Mycosis fungoides, in remission |
| | C84.1A Sézary disease, in remission |
| | C84.4A Peripheral T-cell lymphoma, not elsewhere classified, in remission |
| | C84.6A Anaplastic large cell lymphoma, ALK-positive, in remission |
| | C84.7B Anaplastic large cell lymphoma, ALK-negative, in remission |
| | C84.AA Cutaneous T-cell lymphoma, unspecified, in remission |
| | C84.ZA Other mature T/NK-cell lymphomas, in remission |
| | C84.9A Mature T/NK-cell lymphomas, unspecified, in remission |
| C85 Other specified and unspecified types of non-Hodgkins lymphoma | C85.1A Unspecified B-cell lymphoma, in remission |
| | C85.2A Mediastinal (thymic) large B-cell lymphoma, in remission |
| | C85.8A Other specified types of non-Hodgkin lymphoma, in remission |
| | C85.9A Non-Hodgkin lymphoma, in remission |
| C86 Other specified types of T/NK-cell lymphoma | C86.00 Extranodal NK/T-cell lymphoma, nasal type not having achieved remission<br>C86.01 Extranodal NK/T-cell lymphoma, nasal type, in remission |
| | C86.10 Hepatosplenic T-cell lymphoma not having achieved remission<br>C86.11 Hepatosplenic T-cell lymphoma, in remission |
| | C86.20 Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission<br>C86.21 Enteropathy-type (intestinal) T-cell lymphoma, in remission |
| | C86.30 Subcutaneous panniculitis-like T cell lymphoma not having achieved remission<br>C86.31 Subcutaneous panniculitis-like T-cell lymphoma, in remission |
| | C86.40 Blastic NK-cell lymphoma not having achieved remission<br>C86.41 Blastic NK-cell lymphoma, in remission |

| | |
|---|---|
| | C86.50 Angioimmunoblastic T-cell lymphoma not having achieved remission<br>C86.51 Angioimmunoblastic T-cell lymphoma, in remission |
| | C86.60 Primary cutaneous CD30-positive T-cell proliferations not having achieved remission<br>C86.61 Primary cutaneous CD30-positive T-cell proliferations, in remission |
| C88.0 Waldenström macroglobulinemia | C88.00 Waldenström macroglobulinemia not having achieved remission |
| | C88.01 Waldenström macroglobulinemia, in remission |
| C88.2 Heavy chain disease | C88.20 Heavy chain disease not having achieved remission<br>C88.21 Heavy chain disease, in remission |
| C88.3 Immunoproliferative small intestinal disease | C88.30 Immunoproliferative small intestinal disease not having achieved remission<br>C88.31 Immunoproliferative small intestinal disease, in remission |
| C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma) | C88.40 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission<br>C88.41 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], in remission |
| C88.8 Other malignant immunoproliferative diseases | C88.80 Other malignant immunoproliferative diseases, unspecified not having achieved remission<br>C88.81 Other malignant immunoproliferative diseases, in remission |
| C88.9 Malignant immunoproliferative disease, unspecified | C88.90 Malignant immunoproliferative disease, unspecified not having achieved remission<br>C88.91 Malignant immunoproliferative disease, unspecified, in remission |
| E34.0 Carcinoid syndrome | E34.00 Carcinoid syndrome, unspecified<br>E34.01 Carcinoid heart syndrome<br>E34.09 Other carcinoid syndrome |

| | |
|---|---|
| T45.1 Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs | T45.A Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs<br>Excludes1: poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs<br>T45.AX1 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional)<br>T45.AX2 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm<br>T45.AX3 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault<br>T45.AX4 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined<br>T45.AX4 Adverse effect of immune checkpoint inhibitors and immunostimulant drugs<br>T45.AX4 Underdosing of immune checkpoint inhibitors and immunostimulant drugs |
| Z17 Estrogen, and other hormones and factors receptor status | Z17.2 Progesterone receptor status<br>Z17.21 Progesterone receptor positive status (PR+)<br>Z17.22 Progesterone receptor negative status (PR-) |
| | Z17.3 Human epidermal growth factor 2 receptor<br>Z17.31 Human epidermal growth factor receptor 2 positive status (HER2+)<br>Z17.32 Human epidermal growth factor receptor 2 negative status (HER2-) |
| | Z17.4 Combined receptor status<br>Note: Assign a code when only a combined receptor status is documented.<br><br>Z17.41 Hormone receptor positive<br>Z17.410 Hormone receptor positive with human epidermal growth factor receptor 2 positive status (HR+/HER2+)<br>Z17.411 Hormone receptor positive with human epidermal growth factor receptor 2 negative status (HR+/HER2-)<br><br>Z17.420 Hormone receptor negative |

| | |
|---|---|
| | Z17.420 Hormone receptor negative with human epidermal growth factor receptor 2 positive status (HR-/HER2+)<br>Z17.421 Hormone receptor negative with human epidermal growth factor receptor negative status (HR-/HER2-) |
| Z59 Problems related to housing and economic circumstance | Z59.71 Insufficient health insurance coverage<br>Z59.72 Insufficient welfare support |
| Z92 Personal history of medical treatment | Z92.26 Personal history of immune checkpoint inhibitor therapy |

## Revisions and Updates

Revisions are highlighted in bold.

| Current Language | Revised Language |
|---|---|
| C50 Malignant neoplasm of breast<br>Use additional<br>Code to identify estrogen receptor status (Z17.0, Z17.1) | C50 Malignant neoplasm of breast<br>Use additional<br>Code to identify estrogen receptor status**, and other hormones and factors receptor status (Z17.-)** |
| C7A Malignant endocrine tumors<br>Use additional<br>Carcinoid syndrome (E34.0) | C7A Malignant endocrine tumors<br>Use additional<br>Carcinoid syndrome (E34.0**0**) |
| C83.0 Small cell B-cell lymphoma<br>Excludes 1: Waldenstrom macroglobulinemia (C88.0) | C83.0 Small cell B-cell lymphoma<br>Excludes 1: Waldenstrom macroglobulinemia (C88.0**0**) |
| C83.3 Diffuse large B-cell lymphoma<br>Diffuse large B-cell lymphoma, subtype not specified | C83.3 Diffuse large B-cell lymphoma |
| C84.Z Other mature T/NK-cell lymphomas<br>Excludes1: Angioimmunoblastic T-cell lymphoma (C86.5)<br>Blastic NK-cell lymphoma (C86.4)<br>Enteropathy-type T-cell lymphoma (C86.2) | C84.Z Other mature T/NK-cell lymphomas<br>Excludes1: Angioimmunoblastic T-cell lymphoma (C86.5**0**)<br>Blastic NK-cell lymphoma (C86.4**0**)<br>Enteropathy-type T-cell lymphoma (C86.2**0**) |

| | |
|---|---|
| Extranodal NK-cell lymphoma, nasal type (C86.0)<br>Hepatosplenic T-cell lymphoma (C86.1)<br>Primary cutaneous CD30-positive T-cell proliferations (C86.6)<br>Subcutaneous panniculitis-like T-cell lymphoma (C86.3) | Extranodal NK-cell lymphoma, nasal type (C86.0**0**)<br>Hepatosplenic T-cell lymphoma (C86.1**0**)<br>Primary cutaneous CD30-positive T-cell proliferations (C86.6**0**)<br>Subcutaneous panniculitis-like T-cell lymphoma (C86.3**0**) |
| D05 Carcinoma in situ of breast | D05 Carcinoma in situ of breast<br>**Excludes2: malignant neoplasm of breast (C50.-)** |
| D3A Benign neuroendocrine tumors<br>Use additional<br>Carcinoid syndrome (E34.0) | D3A Benign neuroendocrine tumors<br>Use additional<br>Carcinoid syndrome (E34.0**0**) |
| D61.03 Fanconi anemia | D61.03 Fanconi anemia<br>**Excludes1: Fanconi syndrome (E72.0-)** |
| D89.83 Cytokine release syndrome | D89.83 Cytokine release syndrome<br>**Use additional: code for adverse effect, if applicable, to identify immune checkpoint inhibitors and immunostimulant drugs (T45.AX5)** |
| E09 Drug or chemical induced diabetes mellitus | E09 Drug or chemical induced diabetes mellitus<br>**Use additional injectable non-insulin antidiabetic drugs (Z79.85)** |
| E09.64 Drug or chemical induced diabetes mellitus with hypoglycemia | E09.64 Drug or chemical induced diabetes mellitus with hypoglycemia<br>**Use additional code for hypoglycemia level, if applicable (E16.A-)** |
| E34.0 Carcinoid syndrome<br>Note: may be used as an additional code to identify functional activity associated with a carcinoid tumor. | E34.0 Carcinoid syndrome<br>**Code also the underlying disorder, such as:**<br>**Primary neuroendocrine tumors (C7A.-)**<br>**Secondary neuroendocrine tumors (C7B.-)** |
| T45.1 Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs | T45.1 Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs<br>**Excludes1: poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs (T45.A)** |

| | |
|---|---|
| Z17 Estrogen receptor status | Z17 Estrogen, **and other hormones and factors** receptor status<br>**Note: Use one code, as available for each receptor: Z17.0, Z17.1, Z17.2-, Z17.3-**<br><br>**Code first malignant neoplasm, such as: malignant neoplasm of ovary (C56.-)** |
| Z91.12 Patient's intentional underdosing of medication regimen<br>Excludes1: adverse effect of prescribed drug taken as directed – code to adverse effect<br>poisoning (overdose) – code to poisoning | Z91.12 Patient's intentional underdosing of medication regimen |
| Z91.13 Patient's unintentional underdosing of medication regimen<br>Excludes1: adverse effect of prescribed drug taken as directed – code to adverse effect poisoning (overdose) – code to poisoning | Z91.13 Patient's unintentional underdosing of medication regimen |
| Z91.14 Patient's other noncompliance with medication regimen | Z91.14 Patient's other noncompliance with medication regimen<br>**Code first, if applicable, adverse effect of underdosing (T36-T50)** |
| Z92.2 Personal history of monoclonal drug therapy | Z92.2 Personal history of monoclonal drug therapy<br>**Excludes2: personal history of immune checkpoint inhibitor therapy (Z92.26)** |
| Z92.85 Personal history of cellular therapy | Z92.85 Personal history of cellular therapy<br>**Excludes2: personal history of immune checkpoint inhibitor therapy (Z92.26)** |

# Appendix

## ICD-10-CM Terms and Definitions

Excludes 1: Indicates conditions that may not be reported together. The "Excludes 1" code should not be used at the same time as the code above the note.

Excludes 2: Indicates that although the excluded condition is not part of the condition it is excluded from, the patient may have both conditions at the same time. The Excludes 2 code may be used at the same time as the code above it.

NOS: Not Otherwise Specified. This abbreviation is the equivalent of unspecified.

Use Additional Code: An additional code should be reported to provide a complete picture of the diagnosis.

Code also: More than one code may be required to fully describe the condition.